Dry powder inhalation system
Inventors
Smutney, Chad C. • Kinsey, P. Spencer • Polidoro, John M. • Sahi, Carl R. • Adamo, Benoit • McLean, Scott • Overfield, Dennis • Bryant, Anthony
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12582784-B2
Publication Date
2026-03-24
Expiration Date
Abstract
Dry powder inhaler systems for pulmonary delivery of pharmaceuticals are disclosed.
Core Innovation
The invention provides a method of treating hyperglycemia by administering an inhalable dry powder composition comprising a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from succinyl, glutaryl, maleyl, and fumaryl, via an inhalation system configured for pulmonary delivery. The inhalation system includes a housing with an inlet and an outlet port, and a mouthpiece configured to move translationally within the housing.
The inhalation system is configured to be separable into two principal component parts, and provides an airflow resistance ranging from 0.08 to 0.15 πkPa/liters per minute. The partial document characterizes a breath-activated dry powder inhaler system having a removable mouthpiece and a unit-dose cartridge, designed for rugged, reusable use and ease of cleaning by separating principal components.
The disclosed system includes cartridge airflow mixing behavior in which airflow is split to mix medicament with air via controlled cartridge-through versus around-cartridge distribution, with converging flows prior to exit. Cartridge embodiments include closed-to-open configurations using apertures/windows to create an air passage for aerosolization, supporting tunable airflow resistance to deagglomerate dry powder.
Claims Coverage
The only independent claim explicitly provided is a method claim. It contains multiple structural and functional inventive features, including a specific diketopiperazine composition, pulmonary delivery via an inhalation system with a separable two-part configuration, and a specified airflow resistance range.
Hyperglycemia treatment with diketopiperazine dry powder
A method of treating hyperglycemia by administering an inhalable dry powder composition comprising a diketopiperazine having the formula 2,5-diketo-3,6-di(4-X-aminobutyl)piperazine, wherein X is selected from succinyl, glutaryl, maleyl, and fumaryl, via an inhalation system for pulmonary delivery.
Pulmonary inhalation system with housing and translational mouthpiece
Administering the dry powder via an inhalation system comprising a housing including an inlet and an outlet port, and a mouthpiece configured to move translationally within the housing.
Separability into two principal component parts
Configuring the inhalation system to be separable into two principal component parts.
Airflow resistance range for pulmonary delivery
Configuring the inhalation system to provide an airflow resistance ranging from 0.08 and 0.15 πkPa/liters per minute.
Across the provided independent claim, the core coverage is a hyperglycemia treatment method using a specified diketopiperazine dry powder composition delivered by a separable housing-and-translational-mouthpiece pulmonary inhalation system having an airflow resistance in the stated 0.08 to 0.15 πkPa/liters per minute range.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Not explicitly described in patent.
Interested in licensing this patent?